Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Grows By 28.4%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 6,851,192 shares, an increase of 28.4% from the December 15th total of 5,336,430 shares. Approximately 2.6% of the company’s stock are sold short. Based on an average daily volume of 1,852,007 shares, the days-to-cover ratio is currently 3.7 days. Based on an average daily volume of 1,852,007 shares, the days-to-cover ratio is currently 3.7 days. Approximately 2.6% of the company’s stock are sold short.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 131,856 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the completion of the transaction, the executive vice president owned 146,403 shares of the company’s stock, valued at approximately $1,745,123.76. This trade represents a 47.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ted C. Nark sold 50,000 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $11.72, for a total transaction of $586,000.00. Following the sale, the director directly owned 291,029 shares in the company, valued at $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 231,856 shares of company stock valued at $2,743,724 in the last 90 days. 26.56% of the stock is currently owned by corporate insiders.

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AMRX. BlackBarn Capital Partners LP increased its stake in Amneal Pharmaceuticals by 19.6% during the 2nd quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock worth $27,883,000 after acquiring an additional 564,916 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Amneal Pharmaceuticals by 22.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,332,366 shares of the company’s stock worth $10,779,000 after purchasing an additional 240,676 shares in the last quarter. Walleye Capital LLC increased its position in shares of Amneal Pharmaceuticals by 26.9% in the second quarter. Walleye Capital LLC now owns 708,946 shares of the company’s stock worth $5,735,000 after purchasing an additional 150,104 shares during the period. Squarepoint Ops LLC raised its stake in Amneal Pharmaceuticals by 276.3% in the second quarter. Squarepoint Ops LLC now owns 572,548 shares of the company’s stock valued at $4,632,000 after purchasing an additional 420,398 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Amneal Pharmaceuticals by 1,440.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock worth $11,790,000 after purchasing an additional 1,062,045 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX opened at $13.41 on Monday. The company has a market cap of $4.22 billion, a P/E ratio of 670.84 and a beta of 1.34. The firm’s fifty day moving average price is $12.42 and its two-hundred day moving average price is $10.49. Amneal Pharmaceuticals has a one year low of $6.68 and a one year high of $13.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, October 30th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, equities research analysts expect that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on AMRX shares. Piper Sandler restated an “overweight” rating and issued a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Barclays began coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price for the company. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.80.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.